美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Invesco Nasdaq Biotechnology ETF

34.82

+0.34801.01%

盘后：34.820.00000.00%19:30 EDT

成交量：1.41万

成交额：48.94万

市值：9,679.96万

市盈率：- -

高：34.92

开：34.52

低：34.42

收：34.47

52周最高：36.84

52周最低：23.42

股本：278.00万

流通股本：278.00万

量比：0.80

换手率：0.51%

股息：0.26

股息率：0.74%

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

对外授权交易总额约1100亿美元！2026年上半年创新药“出海”观察：多款获批生物类似药寄望海外收入超越国内

每日经济新闻

创新药板块迎来近一个月最大涨幅，这些国产创新药在“2026世界肺癌大会”读出亮眼数据

每日经济新闻

CRO板块强势走高！多家CRO上市公司解密业务近况

微博财经-财道工作室

我国创新药出海再提速今年对外授权突破1200亿美元

智通港股解盘 | 美国放缓AI另有玄机 WCLC大会再度催化创新药

缩量震荡下，创新药逆市爆发，中证银行指数上探年内新高！光模块回调，高“光”ETF获资金逢低关注

博安生物：BA1203获准开展临床试验

南方财经网

ETF日报：短期看在A股整体市场动能偏弱、热点轮动加快的环境下，前期调整的创新药、CXO板块拥有一定性价比

康哲药业(00867)：创新药高选择性TYK2抑制剂CMS-D001 获得系统性红斑狼疮适应症药物临床试验批准通知书

康哲药业：9月14日CMS-D001获SLE临床试验批准

恒瑞创新药凝血因子XI单抗SHR-2004注射液用于择期膝关节置换手术后成年患者静脉血栓预防的上市申请获受理

白云山：超10个创新药管线引进项目已完成立项

ETF日报(09.14)丨WCLC临床数据密集兑现，创新药板块震荡回升算力需求预期遭重估

阿斯利康(AZN.US)乳腺癌药物Etcamah三期临床试验受挫或致数十亿美元销售额蒙阴

阿斯利康(AZN.US)乳腺癌药物Etcamah三期临床试验受挫或致数十亿美元销售额蒙阴

ETF异动 | 华夏恒生生科(03069)涨超4% WCLC临床数据催化密集机构看好创新药投资机会

【券商聚焦】华创证券维持翰森制药（03692）推荐评级指创新药驱动业绩增长

A股收评：创业板指震荡走低跌1.1%，培育钻石、创新药、MLCC概念板块涨幅居前

创新药闯关医保

国际金融报

港股异动 | 科伦博泰生物(06990)涨超3% POLARIS-1临床试验2期部分取得阳性结果并已启动3期临床

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/IBBQ/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.82,"timestamp":1789416000000,"preClose":34.472,"halted":0,"volume":14094,"hourTrading":{"tag":"盘后","latestPrice":34.82,"preClose":34.82,"latestTime":"19:30 EDT","volume":36,"amount":1244.0123,"timestamp":1789428600873,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01009514968670222,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"未开盘","change":0.348,"latestTime":"09-14 16:00:00 EDT","open":34.52,"high":34.92,"low":34.42,"amount":489401.81775,"amplitude":0.014505,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":34.472,"sharesOutstanding":2520001,"nav":34.43989,"aum":95742928.63989,"dividendRate":0.007412,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.82,"preClose":34.82,"latestTime":"19:30 EDT","volume":36,"amount":1244.0123,"timestamp":1789428600873,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.801497,"impliedVol":0.1149,"impliedVolPercentile":0.4861},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.801497,"shares":2780001,"dividePrice":0.2581,"high":34.92,"amplitude":0.014505,"preClose":34.472,"low":34.42,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.82,"eps":0,"divideRate":0.007412,"volume":14094,"delay":0,"ttmEps":0,"open":34.52,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":36.05,"twentyDayClose":33.8122,"sixtyDayClose":29.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667660668","title":"对外授权交易总额约1100亿美元！2026年上半年创新药“出海”观察：多款获批生物类似药寄望海外收入超越国内","url":"https://stock-news.laohu8.com/highlight/detail?id=2667660668","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667660668?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 01:03","pubTimestamp":1789405401,"startTime":"0","endTime":"0","summary":"2026年上半年，中国创新药延续高增长态势。国家药监局数据显示，2026年1~6月，中国创新药对外授权交易共81笔，总额约1100亿美元，已达2025年全年总额的八成，创历史新高。《每日经济新闻》记者（以下简称每经记者）注意到，从上市公司半年报来看，首付款作为部分企业BD（商务拓展）收入的一部分，让利润表短暂“翻红”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153873800338.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153873800338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","LU1992135399.USD","LU2272731782.SGD","LU2272731600.USD","LU2272731865.HKD","LU2473716301.USD","IE00B5TLWC47.USD","MEDX","BK1161","LNGR","BK1574","06978","LU1992135472.HKD","BK4585","159992","IBB","LU2322448791.USD","LU2322448957.HKD","PPH","XPH","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667366424","title":"创新药板块迎来近一个月最大涨幅，这些国产创新药在“2026世界肺癌大会”读出亮眼数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2667366424","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667366424?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 22:40","pubTimestamp":1789396854,"startTime":"0","endTime":"0","summary":"9月14日，低迷了近一个月的创新药板块迎来上涨。截至收盘，创新药（BK1106）、创新药（HK1105）分别上涨2.38%、3.42%。个股方面，诺诚健华、映恩生物、乐普生物、康方生物领跑港股。消息面上，9月12日—15日召开的“2026世界肺癌大会（WCLC）”成为板块最强催化，多家国产药企密集交出重磅临床数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873752330.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873752330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","IBBQ","159992","BK1161","MEDX","LNGR","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667466104","title":"CRO板块强势走高！多家CRO上市公司解密业务近况","url":"https://stock-news.laohu8.com/highlight/detail?id=2667466104","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667466104?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 21:08","pubTimestamp":1789391280,"startTime":"0","endTime":"0","summary":"在互动平台与机构调研中，多家具备CRO业务的上市公司近期密集回应市场关切，披露了订单、产能及全球化布局的最新进展。2026 年上半年，公司实现 CRO 销售收入 4,513.95 万元， 较上年同期增长 10.91%。截至 2026 年上半年末，客户群体不断扩大，累计服务超过 16,900 家研发实验室客户。CRO 业务毛利率基本保持相对稳定水平，具体受服务类型、项目内容影响有所波动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2026-09-14/doc-inirveaq9305051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ADC","BK4231","MEDX","BK1574","NETL","LNGR","IBBQ","BK1161","06978","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667886669","title":"我国创新药出海再提速 今年对外授权突破1200亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667886669","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667886669?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 20:58","pubTimestamp":1789390730,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667666143","title":"智通港股解盘 | 美国放缓AI另有玄机 WCLC大会再度催化创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2667666143","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667666143?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 20:45","pubTimestamp":1789389921,"startTime":"0","endTime":"0","summary":"科技股的走弱，和 Anthropic、OpenAI 与 SpaceX 罕见联手集体呼吁放缓AI 开发步伐有关。业绩方面，多光谱 AI 大模型服务收入冲到 3.20 亿元，同比暴涨 382.5%，收入占比直接从 29.8% 飙升至 78%。机构认为，2026 年 WCLC 大会的主角仍是 IO2.0 与 ADC，肺癌领域尤其是 1L 非小细胞肺癌的标准治疗范式正处于迭代前夜，国产双抗与 ADC 的进度全球领先。授权品种的里程碑付款与商业化分成，正在成为创新药企业价值兑现的第二曲线。这是公司首款双抗 ADC 获批临床，也是公司第三款 ADC 创新药进入临床。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495830.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0877626530.USD","MEDX","BK1574","BK1566","IE00BGHQDM52.EUR","KCAI","LU0640798160.USD","IBBQ","LU0821914370.USD","IE00BZ08YS42.EUR","LNGR","IE00B29SXG58.USD","KURE","00135","LU1969619763.USD","BK1521","06978","LU0651946864.USD","VXUS","09969","IE00BMCWC346.EUR","IE0034224299.USD","ARTY","02688","LU0593848301.USD","IE00BPRC5H50.USD","LU0287142896.SGD","BK1500","06160","IE0008369823.USD","IE00BZ08YT58.USD","CHAT","LU1051768304.USD","06690","LU1515016050.SGD","IE00BZ08YR35.GBP","LU0431992006.USD","LU0348735423.USD","LU1224709979.USD","AGIX","01193","159992","AIPO","VTHR","LU1808992512.USD","BK1161","BK4588","QTOC","LU0307460666.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668966","title":"缩量震荡下，创新药逆市爆发，中证银行指数上探年内新高！光模块回调，高“光”ETF获资金逢低关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668966","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668966?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 19:10","pubTimestamp":1789384200,"startTime":"0","endTime":"0","summary":"AI硬件赛道普遍回调，受硅谷“降速”言论影响，光模块龙头承压明显，高“光”创业板人工智能ETF华宝标的指数收跌2%，资金逢低关注布局机会。分红方面，国有六大行2026年度中期现金分红总额拟超2000亿元，同时为进一步增强投资者的获得感，均将中期拟分红比例由30%提高至31%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-14/doc-iniruxuu7290017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["399986","AAOX","LYTE","BK1574","06978","MEDX","LUMA","BK4550","FDN","LNGR","159992","BK4585","BK4588","AAOZ","IBBQ","BK1161","AAOG","159253"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668638","title":"博安生物：BA1203获准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668638","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668638?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 19:04","pubTimestamp":1789383840,"startTime":"0","endTime":"0","summary":"南财智讯9月14日电，博安生物（06955.HK）发布自愿公告，公司自主研发的在研PD-1/IL-2抗体细胞因子前药BA1203的新药临床试验申请（IND）已获得中国国家药品监督管理局药品审评中心（CDE）批准，拟开发用于多种实体瘤的治疗。BA1203为全球唯一的IL-2α受体高活性、遮蔽型且PD-1阻断型PD-1/IL-2分子。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873558977.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873558977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["PSYK","BK1161","IBBQ","BMED","MDTX","IBBJ","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667685646","title":"ETF日报：短期看在A股整体市场动能偏弱、热点轮动加快的环境下，前期调整的创新药、CXO板块拥有一定性价比","url":"https://stock-news.laohu8.com/highlight/detail?id=2667685646","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667685646?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 19:02","pubTimestamp":1789383720,"startTime":"0","endTime":"0","summary":"形成赛道级利好共振，重塑市场对创新药研发进度与商业化价值的预期，修复创新药β行情，抬升CXO产业链订单与研发景气度预期。前期创新药、CXO板块经历持续回调，整体估值与市场情绪充分降温，板块点位回落至6-8月宽幅震荡箱体下沿位置，具备一定的技术性反弹空间。展望后市，短期看，在A股整体市场动能偏弱、热点轮动加快、反弹逐步收敛的环境下，前期调整的创新药、CXO板块拥有一定性价比。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-14/doc-iniruxuw4057482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["07233","IBBQ","83188","WX","BK1147","159982","LNGR","02846","159992","BK1161","03188","FDN","MEDX","82846","BK4585","83130","399300","BK4550","06978","CXO","03130","BK1574","02827","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657414","title":"康哲药业(00867)：创新药高选择性TYK2抑制剂CMS-D001 获得系统性红斑狼疮适应症药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657414","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657414?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 18:23","pubTimestamp":1789381419,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 公布，于2026年9月11日，创新药CMS-D001片获得中国国家药品监督管理局签发的药物临床试验批准通知书，于2026年9月14日收到药物临床试验批准通知书。NMPA同意集团开展临床试验以评价CMS-D001治疗系统性红斑狼疮适应症的有效性和安全性。CMS-D001作为高选择性TYK2抑制剂，相较于泛JAK抑制剂，CMS-D001对其他JAK家族激酶的影响较小，可在长期疾病控制中维持疗效并降低相关安全风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LNGR","SG9999015986.USD","SG9999015978.USD","LU2488822045.USD","159992","SG9999015945.SGD","BK1574","IE00BYV24P56.USD","MDTX","SG9999004220.SGD","MEDX","IE00BMCWC346.EUR","IBBQ","BK1593","IBBJ","IE00BVYPNQ40.USD","IE00BVYPNP33.GBP","IE00BGHQDM52.EUR","PSYK","BK1161","SG9999015952.SGD","00867","SG9999004311.SGD","BMED","BK1191","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657480","title":"康哲药业：9月14日CMS-D001获SLE临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657480","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657480?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 18:23","pubTimestamp":1789381383,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","MDTX","BK4077","PSYK","SLE","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657738","title":"恒瑞创新药凝血因子XI单抗SHR-2004注射液用于择期膝关节置换手术后成年患者静脉血栓预防的上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657738","media":"恒瑞医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657738?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 17:59","pubTimestamp":1789379940,"startTime":"0","endTime":"0","summary":"近日，恒瑞医药子公司北京盛迪医药有限公司收到国家药监局下发的《受理通知书》，公司1类创新药、凝血因子XI单克隆抗体SHR-2004注射液的药品上市许可申请获受理，拟定适应症为：用于择期膝关节置换手术的成年患者，以预防静脉血栓形成。该研究旨在评价行择期TKA的患者使用SHR-2004注射液预防静脉血栓栓塞症的有效性和安全性。此外，SHR-2004用于卵巢癌术后VTE预防的Ⅱ期试验已完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-14/doc-iniruxuy4531842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","BK1574","IPOS","MEDX","LNGR","BK1161","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654298","title":"白云山：超10个创新药管线引进项目已完成立项","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654298","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667654298?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 17:36","pubTimestamp":1789378605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667582651","title":"ETF日报(09.14)丨WCLC临床数据密集兑现，创新药板块震荡回升 算力需求预期遭重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2667582651","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667582651?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 16:44","pubTimestamp":1789375451,"startTime":"0","endTime":"0","summary":"WCLC临床数据密集兑现，创新药板块震荡回升；AI巨头集体\"喊停\"，算力需求预期遭重估，通信板块多数走低。行业表现WCLC临床数据密集兑现，国内外投行相继看好中国CRO/CDMO复苏明确，创新药板块震荡回升。消息面上，9月12日至15日，2026年世界肺癌大会在韩国首尔举行，多项国产创新药临床数据集中亮相，中国新药入选口头报告19项、小型口头报告45项，双双刷新历史纪录，肺癌领域ADC与双抗数据成为焦点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4550","AIQD","BK4585","BK4588","159992","FDN","MEDX","BK1161","AIVC","BK1574","LNGR","IBBQ","BAI","EPAI","06978","AIQU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667599986","title":"阿斯利康(AZN.US)乳腺癌药物Etcamah三期临床试验受挫 或致数十亿美元销售额蒙阴","url":"https://stock-news.laohu8.com/highlight/detail?id=2667599986","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667599986?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 16:27","pubTimestamp":1789374476,"startTime":"0","endTime":"0","summary":"Bloomberg Intelligence分析师John Murphy表示，阿斯利康此次乳腺癌药物试验受挫可能使2035年的销售额减少26亿至38亿美元。ESR1突变是ER阳性乳腺癌内分泌治疗耐药的重要机制。CAMBRIA-1比较Etcamah延长辅助治疗5年 vs 标准内分泌治疗，中高复发风险。如果CAMBRIA阳性，Etcamah的市场空间将远大于晚期ESR1突变人群——这也是阿斯利康对Etcamah 50亿美元峰值销售额预期的核心支撑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","PSYK","IBBJ","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667599576","title":"阿斯利康(AZN.US)乳腺癌药物Etcamah三期临床试验受挫 或致数十亿美元销售额蒙阴","url":"https://stock-news.laohu8.com/highlight/detail?id=2667599576","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667599576?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 16:27","pubTimestamp":1789374476,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","BMED","IBBQ","IBBJ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667554366","title":"ETF异动 | 华夏恒生生科(03069)涨超4% WCLC临床数据催化密集 机构看好创新药投资机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2667554366","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667554366?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 15:17","pubTimestamp":1789370250,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华夏恒生生科涨超4%。截至发稿，涨4.01%，报15.58港元，成交额6924.78万港元。本次WCLC会议上，中国新药表现亮眼，入选口头报告研究19项，小型口头报告研究45项，刷新记录。国金证券称，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4550","03069","IBBQ","BK1574","BK4585","06978","159992","MEDX","FDN","BK4588","BK1161","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667655868","title":"【券商聚焦】华创证券维持翰森制药（03692）推荐评级 指创新药驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2667655868","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667655868?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 15:01","pubTimestamp":1789369287,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华创证券发布研报指，翰森制药 2026年上半年实现总营业收入83.04亿元人民币，创新药收入约70.92亿元，占总收入比例约85.4%创历史新高；净利润42.58亿元。研发管线方面，公司创新药临床试验超70项，候选创新药超40个。华创证券指，公司创新药收入驱动业绩稳健增长，BD出海持续推进，在研管线储备丰富，看好聚焦创新和国际化的战略布局。预计2026-2028年营收分别为165.12/185.22/209.34亿元人民币，同比增长9.9%/12.2%/13.0%；归母净利润为61.10/67.78/75.09亿元人民币。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991502","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","KCE","06978","MEDX","03692","LNGR","159992","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667534816","title":"A股收评：创业板指震荡走低跌1.1%，培育钻石、创新药、MLCC概念板块涨幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2667534816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667534816?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 15:01","pubTimestamp":1789369262,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LNGR","MLCC","MEDX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667653941","title":"创新药闯关医保","url":"https://stock-news.laohu8.com/highlight/detail?id=2667653941","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667653941?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 14:46","pubTimestamp":1789368365,"startTime":"0","endTime":"0","summary":"张力制图9月5日至8日，2026年国家基本医保药品目录现场谈判（下称“国谈”）竞价工作在北京开展，上百家国内外药企代表到场参与。本次共有124个目录外药品入围谈判竞价环节，肿瘤、罕见病、慢性病、儿童用药等社会关注度较高的创新药均在列，有望通过谈判纳入新版国家医保目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873368645.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873368645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","BK1574","159992","IBBQ","06978","BK1161","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667658010","title":"港股异动 | 科伦博泰生物(06990)涨超3% POLARIS-1临床试验2期部分取得阳性结果 并已启动3期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2667658010","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667658010?lang=zh_cn&edition=fundamental","pubTime":"2026-09-14 14:36","pubTimestamp":1789367775,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物涨超3%，截至发稿，涨3.35%，报480.8港元，成交额2.53亿港元。消息面上，近日，科伦博泰生物发布公告，公司的合作方Windward Bio AG已公布SKB378/WIN378用于治疗哮喘的POLARIS-1临床试验2期部分取得阳性的中期结果。POLARIS-1的3期部分已由Windward Bio启动，确定采用两种每年两次给药的剂量方案，旨在评估SKB378/WIN378对重度哮喘患者的年化哮喘急性发作率及其他关键疗效指标的影响。POLARIS-1的2期研究数据将在即将召开的医学会议上公布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBJ","BMED","06990","VXUS","MDTX","BK4585","IBBQ","BK4588","KCAI","PSYK","BK1161","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":1,"totalSize":201,"code":"91000000","status":"200"}]}}